cover image: A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-Pd- 1 Monoclonal Antibody BGB-A317 in Combination With the Parp Inhibitor BGB- 290 in Subjects With Advanced Solid Tumors

A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-Pd- 1 Monoclonal Antibody BGB-A317 in Combination With the Parp Inhibitor BGB- 290 in Subjects With Advanced Solid Tumors

2024

16/04/2024 4:19:16 PM A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD- 1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB- 290 in Subjects With Advanced Solid Tumors Clinical summary The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antib
Pages
2
Published in
Australia